Could or Should We Use MCDA in the French HTA Process?

Salah Ghabri (), Jean-Michel Josselin and Benoît Maux
Additional contact information
Salah Ghabri: French National Authority for Health (Haute Autorité de Santé, HAS)
Jean-Michel Josselin: Faculty of Economics, University of Rennes 1, CREM-CNRS
Benoît Maux: Faculty of Economics, University of Rennes 1, CREM-CNRS

PharmacoEconomics, 2019, vol. 37, issue 12, No 2, 1417-1419

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-019-00846-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:37:y:2019:i:12:d:10.1007_s40273-019-00846-w

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-019-00846-w

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().